GlaxoSmithKline GSK and Valeant Pharmaceuticals International, Inc. VRX announced today that the European Commission has granted marketing authorisation for Trobalt (retigabine) as an adjunctive (add-on) treatment of partial onset seizures, with or without secondary generalisation in adults aged 18 years and above with epilepsy.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in